



RM-ICR Early Diagnosis and Detection Centre Launch

When

Friday 10th September 13.00 – 17.00 GMT

Where

Virtual webinar - click [here](#) to register

The **ROYAL MARSDEN**
NHS Foundation Trust

ICR The Institute of
Cancer Research

RM Partners
West London Cancer Alliance

Hosted by The Royal Marsden NHS Foundation Trust

Event overview

The plan for this virtual event is to celebrate the launch of the Early Diagnosis and Detection Centre by bringing together both a local and international audience of Clinicians, Researchers and other Healthcare professionals as well as other ED&D centres nationally and internationally.

The Early Diagnosis and Detection Centre unites early detection research and expertise across multiple tumour groups and clinical trials staff, to maximise research in the early diagnosis setting, to achieve earlier stage clinical diagnoses and help to save lives.

The aim is to showcase early diagnosis expertise within the new centre and highlight future directions for the field. Throughout the afternoon, attendees will be able to learn about the journey of ED&D, future prospects and discuss opportunities to collaborate with the team.

ED&D Centre Leadership

The Early Diagnosis and Detection Centre is a collaboration between The Royal Marsden and The Institute of Cancer Research (RM-ICR). The co-leads of the centre are:

Professor Ros Eeles

Professor of Oncogenetics, The Institute of Cancer Research

Dr Richard Lee

Consultant Respiratory Physician and Champion for Early Diagnosis, The Royal Marsden

Professor Stan Kaye

Professor of Medical Oncology and Research Lead, The Royal Marsden and RM Partners

Agenda

Timing	Name	Topic	Duration
1.00pm	Prof Ros Eeles & Dr Richard Lee	Open and Thanks Chair Session One: Dr Richard Lee	5 mins
1.05	Dame Cally Palmer CEO RM/ Prof Kristian Helin CEO ICR	Launch of the Joint RM/ICR ED&D centre	10 mins
1.15	Prof Ros Eeles	The Case for Risk Stratified Early Diagnosis	15 +5 mins questions
1.35	Dr Richard Lee	Lung Health Checks & RDCs: Taking The National View	15 +5 mins questions
1.55	Dr Anguraj Sadanandam	Early Diagnosis in Cancers of unmet need - developing biomarkers for pancreatic cancer	15 +5 mins questions
2.15	Prof Nick Turner / Prof Vin Paleri	Early diagnosis of Recurrence - Where do we go from here?	20 +5 mins questions

2.40	Break - 15 mins	Chair Session 2: Professor Ros Eeles	
2.55	Dr Angela George	Early Diagnosis in Inherited Cancers	10 +5 mins questions
3.10	Dr Richard Sidebottom	AI, imaging, and Early Diagnosis	10 +5 mins questions
3.25	Prof Clare Turnbull	How does understanding the genome help with early diagnosis?	15 +5 mins questions
3.45	Mr John Butler	Overcoming the Challenges of Early Diagnosis	15 +5 mins questions
4.05	International speaker Prof Pepper Schedin	Early Diagnosis: The global context	20 +5 mins questions
4.30	Dr Richard Lee	Future Directions & Closing Remarks	
	Panel	Virtual Coffee/Wine - Meet & Greet ED Team	30-60

5 mins between talks for questions/change speakers

Dame Cally Palmer



Cally is Chief Executive of The Royal Marsden NHS Foundation Trust and National Cancer Director for NHS England and has held this dual role since 2015. As National Cancer Director, Cally is responsible for the development and implementation of the national strategy for cancer to improve survival and quality of life for all those affected by cancer. She is also a Trustee of the Institute of Cancer Research and a Trustee of The Royal Marsden Cancer Charity

(RMCC).

Cally has an MSc in management with distinction from the London Business School and was awarded a CBE in 2006 and a DBE in 2020 for her contribution to cancer medicine.

Professor Kristian Helin



Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, became Chief Executive of The ICR on 1st September 2021.

Professor Helin is a pioneer in understanding how changes to the way the DNA code is read and translated into protein can lead to cancer. He was the founding Director of a scientific institute


in his homeland of Denmark, led research centres in Italy and the US, and co-founded a successful biotech company.

His appointment underlines the international reputation of The ICR and its ability to attract globally recognised scientific leaders to work here in the UK.

Professor Helin joined The ICR from The Memorial Sloan Kettering Cancer Center in the US, where he was Chair of the Cell Biology Program and Director of the Center for Epigenetics Research (CER) at MSK. He spent 15 years as Director of BRIC – a major biotech and innovation institute at the University of Copenhagen – and was also a Unit and Division Director at the European Institute of Oncology in Milan.

Professor Helin shares The ICR's passion for advancing the scientific understanding of cancer biology, and using that knowledge to drive the discovery and development of innovative cancer treatments that benefit patients.

His work provided preclinical proof that targeting epigenetic regulation could be a promising approach to treating cancer. He also co-founded the biotech company EpiTherapeutics ApS, which successfully discovered new prototype drugs targeted at the regulation of DNA transcription in cancer.



Professor Ros Eeles

Co Chair



Professor Ros Eeles FMedSci, PhD, FRCP, FRCR.

Professor of Oncogenetics, The Institute of Cancer Research (ICR) and Honorary Consultant in Clinical Oncology and Oncogenetics, The Royal Marsden (RM).

Professor Eeles is both a clinician and scientist and her research is in targeted screening in higher risk groups with a genetic predisposition, particularly to prostate cancer.

She is a Team Leader in Oncogenetics at The ICR, and has a programme of research in genetic predisposition to prostate cancer and management of individuals with BRCA and other DNA repair gene mutations. She leads the largest prostate cancer genetic study in the UK, set up an international consortium that involves over 100 research groups worldwide, and leads multiple clinical trials and screening studies. She also started the flagship Prostate Risk Clinic at The Royal Marsden to evaluate the increasing role of genetic testing in men with and at risk of prostate cancer.

She has sat on many genetics advisory committees, both national and international. She is the Genomics Champion for the Royal College of Radiologists (Clinical Oncology Faculty) for the Academy of Royal Colleges. She is an author of over 500 papers and her book which she led as lead editor 'Cancer Prevention and Screening' won the BMA Chairman's Book of the Year Award in 2019.

Dr Richard Lee

Co Chair



Dr Richard Lee MA Hons (Cantab), MBBS, MRCP PhD.

Dr Lee is a Consultant Respiratory Physician and Champion for Early Cancer Diagnosis at RM-ICR Biomedical Research Centre. His clinical interest is early lung cancer diagnosis, as joint National Clinical Lead of the NHS England National Targeted Lung Health Check (TLHC) Program, that will pilot lung cancer screening in over 1 million participants across the UK. He also leads early diagnosis clinical innovation and research initiatives across all cancer types.

His research portfolio includes translation of artificial intelligence research to early cancer detection within the LIBRA, OCTAPUS-AI and AI-SONAR Studies. He is also PI for early diagnosis biomarker studies such as NIMBLE for lung nodules and RM Partners Lung Health Check biomarker study. As clinical lead for the DART biomarker study, he will link biomarker and AI techniques within NHSE TLHC in partnership with Oxford University.

As The Royal Marsden Chief Research Information Officer, Dr Lee applies data science and informatics to cancer research more broadly. He also serves on the BTS lung cancer committee, co-leads the Early Diagnosis theme of the Joint ICR-Imperial Convergence Science Centre and NIHR Oncology-TRC. He also peer-reviews for a number of grant bodies and journals, including the CRUK Early Diagnosis Committee and ERS College of Experts.

His role and work in Early Diagnosis is funded by The Royal Marsden Cancer Charity (RMCC), with whom he works closely to promote early diagnosis amongst patients and colleagues.

Twitter: @ChestConsultant

Professor Stan Kaye



Stan Kaye, Professor of Medical Oncology and Research Lead, The Royal Marsden and RM Partners.

Professor Stan Kaye has been based in London since 2000, at The Royal Marsden and Institute of Cancer Research, where he was Head of the Division of Clinical Studies until his retirement from The ICR in 2013. At The Royal Marsden, he was Head of the Drug Development Unit, and was also responsible for

the management of patients with gynaecological cancer. He continues to work at The Royal Marsden as Senior Research Fellow in the Biomedical Research Centre and Professor of Medical Oncology.

In May 2014 he was appointed as RM Partners West London Cancer Alliance Research and Development Director. In that role he is responsible for promoting the whole spectrum of research across the Alliance, with a focus on early diagnosis and the translation of research into clinical practice to support innovative models of service delivery. He also chairs the pan-London Cancer Alliance Research Board as well as the recently convened NIHR Oncology Translational Research Collaborative.

Professor Kaye qualified in medicine in London in 1972 and in 1981 moved to Glasgow, where he was Head of the Department of Medical Oncology at Glasgow University from 1985-2000. He has published over 450 papers on a range of topics, including ovarian cancer and early drug development. He is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Science. He also has an honorary Doctorate of Science from the University of London. He holds an Emeritus Chair at The ICR and has visiting Chairs in Glasgow and Singapore. In 2016 he received the Lifetime Achievement Award from Cancer Research UK.

Dr Anguraj Sadanandam



Dr Sadanandam is a Director, Centre for Global Oncology and Reader in Stratified and Precision Medicine at The ICR since 2013. He is currently applying his multidisciplinary skills to integrated science of stratified medicine to understand inter- and intra-tumoural/immune heterogeneity, normal-tumour evolution/progression and test precise therapies for different subtypes of cancers using computational (artificial intelligence), experimental (including pre-

clinical in vitro and in vivo models) and clinical (accessing clinical trial samples by developing companion diagnostics) biology.

Dr Sadanandam led the research work to define transcriptome/multi-omics subtypes of pancreatic, colorectal, gastroesophageal, and breast cancers associated with prognosis and potential personalised medicine (multiple high-impact Nature Medicine, Cancer Cell, Cancer Discovery, Cell, Science and other publications out of more than 60 publications). These subtypes and classifications are highly cited and applied by the research and clinical communities. He is a major contributor in multiple consortia including ColoRectal Cancer Subtyping Consortium (CRCSC; Guinney et al., Nature Medicine 2015) and clinical trials.

Dr Sadanandam initiated the Centre for Global Oncology at The ICR and currently co-ordinates multiple projects related to Global (specifically Low-Middle Income Countries including India) Cancer Research. He is also one of the Advisors of Indian Cancer Genome Atlas (ICGA) project.

Professor Nick Turner



Professor Nicholas Turner is a Consultant Medical Oncologist who specialises in the treatment of breast cancer. He read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School. After completing general medical training in London, he trained in medical oncology at Royal Free and University College Hospitals before completing a PhD at The ICR in 2006. He joined The Royal Marsden Breast Unit as a Consultant in Medical Oncology in 2008.

He is a Team Leader in Molecular Oncology at the Breast Cancer Now Research Centre at The ICR. He is Genotyping, Phenotyping and Cancer Evolution Theme Lead for The Royal Marsden and ICR NIHR Biomedical Research Centre.

Professor Turner is the Breast Domain Lead of the Genomics England Clinical Interpretation Partnerships, and has co-chaired the ASCO/CAP review committee on circulating tumor DNA analysis in patients with cancer. He sits on the organising committees of many international conferences on breast cancer, was the executive chair of the IMPAKT 2015 breast cancer conference, and is a scientific editor of the Cancer Discovery journal. He is Chief Investigator of a number of national and international trials of precision therapy in breast cancer. His research interests include the development of new therapies for breast cancer and using liquid biopsies to deliver more precise treatment for breast cancer.

Professor Vinidh Paleri



Professor Vin Paleri is one of the few surgeons in the United Kingdom with expertise in Transoral Robotic Surgery and Transoral Laser Microsurgery for head and neck cancers and has accrued the largest experience in Transoral Robotic Surgery in the UK. He has pioneered a new robotic technique to remove radiorecurrent and radioresidual cancers and is the first surgeon in the UK to perform robotic free flap reconstructions.

He is the primary or co-recipient for over £4 million in grant funding, has published over 200 papers, and co-edited the fourth and fifth editions of the UK National Head and Neck Cancer Multidisciplinary Management Guidelines. He has also edited the volume on “Head and Neck Disease” for the 8th edition of Scott-Brown’s Otolaryngology, the leading multi-volume, multi-author textbook in the specialty globally. He is also chief editor for the forthcoming 6th edition of Stell & Maran’s Textbook on Head and Neck Surgery and Oncology.

Vin is an Associate Editor for Head and Neck, the top ranked journal in the field, Senior Reviews Editor for the Journal of Laryngology and Otology, one of the oldest journals in the field (est. 1887), and serves on the editorial board for several other leading journals in the specialty. He currently serves as President of the research council for the British Association of Head and Neck Oncologists. Vin is Director of the International Centre for Recurrent Head and Neck Cancer at The Royal Marsden, and serves as member of the following national bodies: ENT-UK Head & Neck Society and the Laryngology & Rhinology Section of the Royal Society of Medicine.

Dr Angela George



Dr Angela George is a Consultant Medical Oncologist and Consultant in Oncogenetics at The Royal Marsden. She specialises in the systemic treatment of gynaecological cancers, her focus area is the use of genomic information in treatment. She is also Clinical Director of Genomics at The Royal Marsden, and undertakes testing for inherited cancer syndromes in her oncogenetics practice.

Dr George trained initially in New Zealand in Medical Oncology, before moving to The Royal Marsden and undertaking additional Oncogenetics training at The ICR, where she was awarded the Chairman's Prize for her Thesis in Ovarian Cancer Genetics. She led the implementation of the Cancer Genetics programme, which involved incorporating genetic testing into the routine care of patients with ovarian, breast and pancreatic cancers. These programmes have now been adopted across the UK and Dr George has helped set these programmes up internationally, expanding into multiple tumour types, and revolutionising the use of routine genomic information.

Dr George is involved in multiple groups, including the National Cancer Research Institute Gynaecological Cancers Group, the Precision Medicine working group for the European Society of Medical Oncology and the British Society of Genetic Medicine. She is the Cancer Clinical Lead for the North London Genomic Medicine Service and co-chairs the molecular tumour board.

Dr George has authored multiple publications/book chapters, and undertakes a variety of clinical and translational research, particularly in cancer genomics and targeted treatments. She is also the principal investigator at The Royal Marsden for multiple international trials.

Dr Richard Sidebottom



Richard is a consultant radiologist specialised in breast imaging. His NHS clinical practice is at Cheltenham.

He holds a research radiology post at The Royal Marsden as part of the AI imaging hub where his current research work involves dataset extraction and curation from routinely collected patient records. He previously conducted a clinical trial of a novel breast imaging system at The Royal Marsden.

Richard has an MSc in biomedical engineering and is interested in the future development of imaging technologies. He has been a paid consultant to DeepMind health/Google health since 2017 and in 2020 contributed to a publication in Nature and was successful in applying for NHSx AI funding which was awarded in 2021. He continues to be involved in their work in mammography analysis and application.

Richard is a member of the CRUK OPTIMAM project advisory board.

Professor Clare Turnbull



Professor Clare Turnbull is Professor of Translational Cancer Genetics in the Division of Genetics and Epidemiology at The ICR. Her research spans statistical, population and public-health-related analyses of genetic cancer susceptibility and implementation of expanded genomic testing. She is currently rolling out a new £4.3 million CRUK-funded program: 'CanGene-CanVar: Data Resources, Clinical and Educational Tools to leverage Cancer Susceptibility

Genetics for Early Detection and Prevention of Cancer' program.

As an honorary consultant in Public Health, she is working closely with Public Health England in this program to incorporate genomic data into the National Cancer Registration datasets. She is also in the process of initiating BRCA-DIRECT: a CRUK-funded program to develop and pilot a digital platform to deliver BRCA testing, enabling extension of testing to all women with breast cancer. Undertaking germline, somatic and functional genomic studies in various tumour types, Professor Turnbull has a particular interest in testicular cancer. Her team has led the international field in identification of genetic factors influencing testicular germ cell tumorigenesis.

Having trained as a Clinical Geneticist, her clinical work at The Royal Marsden focuses on management of patients and families with genetic susceptibility to cancer. From 2014 to 2020, Professor Turnbull worked as Clinical Lead for Cancer Genomics for the Genomics England 100,000 Genomes Project.

Mr John Butler



Mr John Butler is a gynaecological surgeon. He is certified as both a specialist gynaecologist and sub-specialist gynaecological oncology by the RCOG. He qualified in medicine from St Mary's Hospital in 2000 and continued his postgraduate training in London, including his oncology training at The Royal Marsden and St Bartholomew's Hospital.

He has an active research portfolio and has published extensively on gynaecological cancer, international cancer survival, and cancer policy.

He is the lead clinician to the International Cancer Benchmarking Partnership, chair of the Cancer Research UK clinical advisory committee, gynaecology pathway chair for RM Partners and medical director of the Lady Garden Foundation.

His main interests include ultra-radical gynaecological cancer surgery, fertility-preserving surgery for cervical cancer, minimal access surgery, risk-reducing surgery for BRCA, and vulval cancer.

Professor Pepper Schedin



Dr Pepper Schedin is a Professor in the Department of Cell, Developmental and Cancer Biology at Oregon Health & Science University, and Co-Director of the Young Women's Translational Breast Cancer Program at the University of Colorado, Anschutz Medical Center. Dr. Schedin has Co-led the Cancer Prevention and Control Program within the Knight Cancer Institute at OHSU, and currently serves as Chair of the SOM Early Career Faculty Advancement Program.

The Schedin lab is at the forefront of investigating stroma in the normal mammary gland and in breast cancer models, and has shown that fibroblasts, immune cells and extracellular matrix composition are highly plastic, remodeling in response to various reproductive signals. The Schedin lab is also the first to report the phenomenon of weaning-induced liver involution and has gone on to provide potential translational relevance by porting higher rates of liver metastasis in early onset postpartum patients than expected.

This work demonstrates that stromal plasticity, while physiologically normal, contributes significantly to breast cancer progression, especially in early onset disease. This work also identifies unique reproductive-windows that can be targeted for the early detection and prevention of breast cancer. For cancer treatment, this work adds a woman's individual reproductive history as a clinical variable to be included in treatment decisions.



For further details, please contact:

Shafa Ullah

Research Operations Lead Early Diagnosis &
Detection (ED&D)

The Royal Marsden NHS Foundation Trust

shafa.ullah@rmh.nhs.uk

Or visit the website royalmarsden.nhs.uk/early-diagnosis-and-detection-centre



Funded by

